Sobi Exits Nirsevimab Cost-Sharing Pact With AstraZeneca, Simplifies Royalty Deal With Sanofi

 
• By Joseph Haas

Deal Snapshot: Approved in the EU/UK and nearing a US approval, rights to the RSV prophylaxis for infants and newborns are simplified in the pair of agreements unveiled by Synagis owner Sobi.

Businessman sinking in heap of documents and asking for help
Sobi says new agreements simplify rights pertaining to nirsevimab

More from Deals

More from Business